Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum

Vishnu Girish, Rakhi Maiwall

Clin Mol Hepatol. 2025;31(3):730-752. Published online March 26, 2025

DOI: https://doi.org/10.3350/cmh.2024.1060

View: 1264 Download: 154

Correspondence

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e212-e214. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0100

View: 831 Download: 22

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e161-e162. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0121

View: 824 Download: 30

Letter to the Editor

Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Rui Shi, Minghua Wang

Clin Mol Hepatol. 2025;31(2):e137-e139. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.1159

View: 951 Download: 45 Web of Science: 1 Crossref: 1

Editorial

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Jongman Kim

Clin Mol Hepatol. 2025;31(2):589-591. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0076

View: 961 Download: 40 Web of Science: 1 Crossref: 1

Original Article

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):131-146. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0451

View: 2082 Download: 193 Web of Science: 4 Crossref: 2

Review

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 2928 Download: 203 Web of Science: 2 Crossref: 3

Letter to the Editor

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 2218 Download: 110 Web of Science: 3 Crossref: 4

Original Article

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function

Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique

Clin Mol Hepatol. 2017;23(4):316-322. Published online August 22, 2017

DOI: https://doi.org/10.3350/cmh.2016.0087

View: 8589 Download: 193 Web of Science: 12 Crossref: 16

Editorial

Use of sofosbuvir in chronic kidney disease: Is it necessary?

Tae Seop Lim, Sang Hoon Ahn

Clin Mol Hepatol. 2017;23(4):308-310. Published online September 26, 2017

DOI: https://doi.org/10.3350/cmh.2017.0109

View: 6837 Download: 120 Web of Science: 4 Crossref: 6

Original Article

Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal

Yun Jung Choi, Jeong Han Kim, Ja Kyung Koo, Cho I Lee, Ji Young Lee, Jae Hoon Yang, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee

Clin Mol Hepatol. 2014;20(2):185-191. Published online June 30, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.2.185

View: 10694 Download: 122 Web of Science: 37 Crossref: 30

1 |

Viewed By 12501	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7615	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7079	MAFLD: How is it different from NAFLD?
Viewed By 5670	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5543	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search